



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 12-7-2008

Mr. Yasin Tahir,  
Director General, IPO-Pakistan  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 21-6-2008 TO BE PUBLISHED 14-7-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 12-7-2008

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 21-6-2008 TO BE PUBLISHED 14-7-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## **NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

|          |  |   |
|----------|--|---|
| 698/2008 | <b><u>16-6-2008</u></b><br>Bayer Schering Pharma<br>Aktiengesellschaft<br>Germany<br>(Priority 12-7-07 Europe)   | “8-beta-substituted estratrienes as<br>selectively active estrogens”    |
| 699/2008 | <b><u>17-6-2008</u></b><br>Johnson Matthey PLC,<br>United Kingdom<br>(Priority 18-6-07 GB)                       | “Novel water-stable compounds catalysts,<br>and catalysed reactions”    |
| 700/2008 | Honda Motor Co., Ltd.<br>Japan<br>(Priority 18-6-07 Japan)   | “Vehicle body side structure”   |
| 701/2008 | Pierre Fabre Medicament<br>France<br>(Priority 19-6-07 France)   | “Use of a Par-1 antagonist for the treatment<br>of atrial fibrillation” |
| 702/2008 | Boehringer Ingelheim<br>International GmbH,<br>Germany<br>(Priority 19-6-07 Europe)                              | “Anti-IGF antibodies”   |
| 703/2008 | Urea Casale S. A.,<br>Switzerland<br>(Priority 27-6-07 Europe)   | “Granulation process and apparatus”                                     |
| 704/2008 | <b><u>18-6-2008</u></b><br>1.Zahida N. Umar,<br>2. Nida Saleem,<br>3. Muhammad Kamran<br>PCSIR, Karachi Pakistan | “A process for the production of<br>persimmon candies”                  |
| 705/2008 | AstraZeneca AB,<br>Sweden<br>(Priority 19-6-07 USA)  | “Compounds and uses thereof-849”  |
| 706/2008 | AstraZeneca AB,<br>Sweden  | “Compounds and uses thereof-848”  |

(Priority 19-6-07 USA)

|          |   |  |
|----------|---|--|
| 707/2008 | Uster Technologies AG,<br>Switzerland<br>(Priority 19-6-07<br>Switzerland)        | “A device and method for testing moved<br>textile materials”             |
| 708/2008 | Honda Motor Co. Ltd,<br>Japan<br>(Priority 19-6-07 Japan)                         | “Vehicle body floor structure “  |
| 709/2008 | Glaxo Group Limited,<br>United Kingdom<br>(Priority 20-6-07 USA)                  | “Spiroindolines as modulators of<br>chemokine receptors”                 |
| 710/2008 | Schering Corporation,<br>USA<br>(Priority 21-6-07 USA)                            | “Polycyclic guanine derivatives and<br>methods of use thereof”           |
|          | <b><u>19-6-2008</u></b>   |  |
| 711/2008 | IRM LLC.<br>Bermuda.<br>(Priority 20-06-2007 USA)                                 | “Methods and composition for treating<br>allergic diseases”              |
| 712/2008 | Eli Lilly and Company,<br>USA,<br>(Priority 17-07-2007 USA)                       | “Potentiation of cancer chemotherapy”                                    |
| 713/2008 | Sirtris Pharmaceuticals, Inc.<br>USA.<br>(Priority 20-06-2007 USA)                | “Sirtuin modulating compounds”   |
| 714/2008 | Sirtris Pharmaceuticals, Inc.<br>USA.<br>(Priority 20-06-2007 USA)                | “Sirtuin modulating compounds”   |
| 715/2008 | Mitsubishi Tanabe Pharma<br>Corporation.<br>Japan.<br>(Priority 20-06-2008 Japan) | “Novel sulfonyl malonamide derivative<br>and pharmaceutical use thereof” |
|          | <b><u>20-6-2008</u></b>   |  |
| 716/2008 | LEO Pharma A/S.<br>Denmark.<br>(Priority 21-06-2007 USA)                          | “Substituted acetophenones useful in<br>therapy”                         |

|          |   |  |
|----------|---|--|
| 717/2008 | Honda Motor Co. Limited.<br>Japan.<br>(Priority 22-06-2007 Japan)   | “Rear vehicle body structure”  |
| 718/2008 | Sanofi-Aventis Deutschland<br>GmbH.<br>Germany.<br>(Priority 22-06-2007 USA)  | “Process for preparing benzyl<br>pentahydroxyhexylcarbamoyleundecanoate”             |
| 719/2008 | Lenzing Aktiengesellschaft.<br>Austria.<br>(Priority 21-06-2007 Austria)  | “Thin film treatment apparatus”  |
| 720/2008 | Lenzing Aktiengesellschaft.<br>Austria.<br>(Priority 21-06-2007 Austria)  | “Thin film treatment apparatus”  |
| 721/2008 | Lenzing Aktiengesellschaft.<br>Austria.<br>(Priority 21-06-2007 Austria)  | “Thin Film Treatment apparatus”  |
| 722/2008 | Yuhan Corporation .<br>Korea.<br>(Priority 21-12-2007 Korea)  | “Revaprazan-containing solid dispersion<br>and process for the preparation thereof “ |
| 723/2008 | Sanofi-Aventis.<br>France.<br>(Priority 21-06-2007 France)  | “Novel substituted indazoles, preparation<br>thereof and therapeutic use thereof”    |
| 724/2008 | Otsuka Pharmaceutical Co.<br>Limited.<br>Japan.<br>(Priority 21-06-2007 Japan)  | “Pharmaceutical solid preparation and<br>production method thereof”                  |
| 725/2008 | Anacor Pharmaceuticals, Inc.<br>USA.<br>(Priority 20-06-2007 USA)   | “Boron-containing small molecules”   |
| 726/2008 | <b><u>21-6-2008</u></b><br>1.Dr. Shahid Iqbal.<br>2.Dr. Muhammad Iqbal<br>Bhanger.<br>3.Dr. Mubeena Akhtar.<br>Pakistan. Sindh. | “A herbal antioxidant system for chewing<br>gum stability”                           |

|          |  |   |
|----------|--|---|
| 727/2008 | Douglas C. Comrie.<br>USA.   | “Methods of operating a coal burning facility”                              |
| 728/2008 | Douglas C. Comrie.<br>USA.   | “Apparatus for delivery of sorbent to a furnace during combustion”          |
| 729/2008 | ChemoCentryx, Inc.<br>USA.<br>(Priority 22-06-2007 USA)                            | “N-(2-(hetaryl)arylsulfonamides and N-(2-(hetaryl)Hetaryl)arylsulfonamides” |
| 730/2008 | Oerlikon Textile GmbH &<br>Co. Kg.<br>Germany.<br>(Priority 22-06-2007<br>Germany) | “Transport apparatus in a spinning plant”                                   |

\*\*\*\*\*

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

|         |                             |   |        |
|---------|-----------------------------|---|--------|
| 35/2002 | Merck & Co.<br>Inc.<br>USA. | “Nucleoside compound as inhibitor of RNA-dependent<br>RNA viral polymerase”<br><br>(C07H 19/06) | 139618 |
|---------|-----------------------------|---|--------|




The present invention provides nucleoside compound which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compound of the present invention.

|          |                                 |  |        |
|----------|---------------------------------|--|--------|
| 599/2003 | Pfizer Products<br>Inc.<br>USA. | “phenanthrene compound”<br><br>(C07D 211/04) | 139619 |
|----------|---------------------------------|--|--------|

The present invention provides compound of the formula.



wherein A is of the formula



And X, Y, n, R<sup>1</sup>-R<sup>25</sup> are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.


747/2003 Pfizer Products Inc. USA.

“Novel benzoimidazole compound”

(C07D 215/38, A61K 31/47)

139620

The invention relates to compound of the formula 1



Wherein each  $R^1$ ,  $R^2$ , and  $R^3$  is independently selected from H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl, halo, cyano,  $CF_3$ , difluoromethoxy, trifluoromethoxy,  $OC_1$ - $C_6$  alkyl,  $OC_3$ - $C_6$  cycloalkyl, and  $NR^7R^8$ ;  $R^4$  is  $-(CR^5R^6)_nH$ , or  $-(CR^5R^6)_m$  (4 to 10 membered heterocyclic), wherein n is an integer ranging from 1 to 5, wherein m is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3  $R^1$  substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by 1 to 3  $R^7$  substituents at any position and optionally substituted by 1 to 3  $R^9$  substituents at any position not adjacent to or directly attached to a heteroatom;

The invention also relates to method of treating abnormal cell growth, such as cancer, in mammals by administering the compound of formula 1 and to pharmaceutical composition for treating such disorders which contain the compound of formula 1.

417/2004 AstraZeneca  
AB.  
Sweden.

“A potassium salt or a sodium salt of (-)-2-{{2-(4-hydroxyphenyl)ethyl}thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid”

(C07C 53/122)

139621

A potassium salt or a sodium salt of (-)-2-{{2-(4-hydroxyphenyl)ethyl}thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)propanoic acid their use in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical composition containing them.


1013/2004 Pfizer Products  
Inc.  
USA.

“Pyrido[2,3-d]pyrimidine-2,4-diamine compound”

(C07D 471/02)

139622

The invention provides compound of formula (I)



Wherein

n is 1, 2, 3, or 4;

X is a bond; O; S; C=O; -N(R)-, wherein R is hydrogen or -(C<sub>1</sub>-C<sub>3</sub>)alkyl; -C(OH)-; or -SO<sub>2</sub>; and

Y is benzoxazolyl; benzothiazolyl; benzofuranyl; benzofuranyl; benzothiadiazolyl; benzisoxazolyl; benzisothiazolyl; benzimidazolyl; pyridyl; isatinyl; oxindolyl; indazolyl; Indolyl; phenyl; thienyl; or furanyl; pharmaceutical composition thereof; combination thereof; and uses thereof.

994/2006 Merck & Co.  
Inc.

And

Isis  
Pharmaceuticals,  
Inc.  
USA.

“A pharmaceutical acceptable salt of nucleoside compound as inhibitor of RNA-Dependent RNA viral polymerase”

(C07H 19/06)

139623

The present invention provides a pharmaceutically acceptable salt of a compound selected from the group consisting of:

4-amino-7-(2-C-methyl-β-D-arabinofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine,

4-amino-7-(2-C-methyl-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine,

4-amino-7-(2-C-fluoromethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine,

4-amino-5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine,

4-amino-5-bromo-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine,

4-amino-5-chloro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-*d*]pyrimidine,  
4-ammo-5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[23-*d*]pyrimidine,  
and 4-amino-7-(2-C,2-0-dimethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-*d*]pyrimidine.

These are inhibitors of RNA-dependent RNA viral polymerase. These salts are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

717/2000 Bristol-Myers  
Squibb Co.  
USA.

“A pharmaceutical composition comprising entecavir”

(A61K 31/52)

139624

Compositon containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulation for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately admunistered for the treatment of hepatis B virus infection or for the treatment of co-infected patients.



**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

|        |   |          |
|--------|---|----------|
| 139322 | Merck & Co. Inc,                        | 465/2001 |
| 139323 | Bristol-Myers Squibb Company,<br>USA    | 433/2003 |
| 139324 | F. Hoffmann-La Roche AG,<br>Switzerland | 722/2003 |

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Tel: 9215488